¡¾²Î¿¼ÎÄÏס¿

  ¡¡1 Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol 2005;123(1):64ª²70.Erratum in: Arch Ophthalmol 2005;123(4):574

¡¡¡¡2 Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007;67(5):725ª²759

¡¡¡¡3 Bakalash S, Kipnis J, Yoles E, et al. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005;15;233(1ª²2):163ª²166

¡¡¡¡4 Schwartz M. Modulating the immune system: a vaccine for glauª²coma? Can J Ophthalmol 2007;42(3):439ª²441

¡¡¡¡5 Ben Simon GJ, Bakalash S, Aloni E, et al. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. Am J Ophthalmol 2006;141(6):1105ª²1111

¡¡¡¡6 Blair M, Pease ME, Hammond J£¬ et al. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci 2005;46(3):884ª²890

¡¡¡¡7 Johnson EC, Deppmeier LM, Wentzien SK, et al. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2000;41(2):431ª²442

¡¡¡¡8 Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol 2004;58(3):341ª²354

¡¡¡¡9 Lin ZP, Zhu YL, Johnson DR, et al. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Invest Ophthalmol Vis Sci 2005;46(11):4164ª²4169

¡¡¡¡10 Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007;67(5):725ª²759

¡¡¡¡11 Orgul S, Zawinka C, Flammer J, et al. Therapeutic strategies for normalª²tension glaucoma. Ophthalmologica 2005;219(6):317ª²323

¡¡¡¡12 Gherghel D, Griffiths HR, Hilton EJ, et al. Systemic reduction in glutathione levels occurs in patients with primary openª²angle glauª²coma. Invest Ophthalmol Vis Sci 2005;46(3):877ª²883

¡¡¡¡13 Ko ML, Peng PH, Ma MC. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med 2005;39(3):365ª²373

¡¡¡¡14 Lsiz N, Sahaboglu A, Yildiz MZ , et al. Protective effects of various antioxidants during ischemiaª²reperfusion in the rat retina. Graefes Arch Clin Exp Ophthalmol 2006;244(5):627ª²633

¡¡¡¡15 Cellini M, Caramazza N, Mangiafico P, et al. Fatty acid use in glaucomatous optic neuropathy treatment. Acta Ophthalmol Scand Suppl 1998;(227):41ª²42

¡¡¡¡16 Siegmund B, Zeitz M. Pralnacasan (vertex pharmaceuticals). Drugs 2003;6(2):154ª²158

¡¡¡¡17 Aktas Z, G¨¹relik G, Aky¨¹rek N, et al. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelinª²1ª²induced optic nerve ischaemia model. Clin Experiment Ophthalmol 2007;35(6):527ª²534

¡¡¡¡18 Schlieve CR, Tam A, Nilsson BL, et al. Synthesis and characterization of a novel class of reducing agents that are highly neuroprotective for retinal ganglion cells. Exp Eye Res 2006;83(5):1252ª²1259

¡¡¡¡19 Wood JP, Schmidt KG, Melena J, et al. The betaª²adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res 2003;76(4):505ª²516

¡¡¡¡20 Goto W, Ota T, Morikawa N, et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 2002;958(1):10ª²19

¡¡¡¡21 Fuchsjgerª²Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005;89(10):1293ª²1297

¡¡¡¡22 Qiu JH, Liu XY, Wu ZQ. Retrospection and expectation on drug management of glaucoma. Int J Ophthalmol (Guoji Yanke Zazhi) 2007;7(3):754ª²758

¡¡¡¡23 Fan XR, Sun H. Advances in researches on the optic nerve protection. Int J Ophthalmol(Guoji Yanke Zazhi) 2006;6(6):1267ª²1271

¡¡¡¡24 Zou YH, Chiou GGY. Newidens for medical therapy of glaucoma in the fature. Int J Ophthalmol (Guoji Yanke Zazhi) 2005;5(3):411ª²422

ÉÏÒ»Ò³  [1] [2] [3] [4]